About Versamune®

Versamune® is a proprietary T-cell activating platform technology designed to train the immune system to better attack and destroy cancer.  Versamune® delivers a powerful tumor-specific T-cell response with minimal side effects compared with most other cancer-fighting therapies and is engineered for simplicity and ease of administration.

Versamune® Mechanism of Action Video


Versamune®, when combined with antigens tailored for specific cancers, is demonstrated to:

Group 148 
Promote a large quantity of antigen-specific T-cells, tailored to attack a specific cancer type
 Group 147
Induce a highly potent type of T-cell that is targeted to kill cancer

 Group 144
Deliver a powerful immune response associated with cancer regression
Group 149 
Substantially improve the activity of a proven blockbuster cancer-fighting technology - checkpoint inhibiters - when administered in combination with Versamune®
 Group 161
Deliver potency with minimal side effects – to date limited to transient injection site reactions without triggering more severe systemic side effects


The Versamune® platform is comprised of structure-specific positively charged (cationic) lipids with custom-designed antigens for different types of cancer.  These combinations, delivered via simple subcutaneous injection, have proven to stimulate the activation of immunologic pathways associated with increased cancer-fighting activity.

Versamune® is based on immune-activating cationic lipids such as the R-enantiomer of 1,2-dioleoyl-e-trimethyl-ammonium-propane (R-DOTAP). This lipid spontaneously assembles into nanoparticles in a water-based medium and is engineered to mimic an artificial virus.  This promotes efficient uptake by dendritic cells, the antigen presenting cells of the immune system.  Versamune® has been demonstrated to promote cross-presentation of the antigen to both CD4+ helper and CD8+ killer T-cells. Versamune® has also been proven to activate the Type I Interferon pathway within the lymph nodes, leading to superior recruitment and priming of polyfunctional, highly potent T-cells.


Versamune® has been shown to induce in vivo significantly higher quantity and quality of highly potent (polyfunctional) killer T-cells, a specific sub-type of killer T-cell that is more powerful at attacking cancer, than other cancer-fighting technologies.  This superior quantity and quality of antigen-specific killer T-cells generated by Versamune® results in more effective cancer treatments.

Versamune®-based products demonstrate impressive efficacy when used alone.  However, when the powerful immune response of Versamune® is added to proven checkpoint inhibitor therapies, which help “unmask” cancer tumors, the two technologies have been demonstrated in early studies to work synergistically to attack and destroy cancer cells more effectively than either alone.

Versamune® avoids potentially systemic toxicities associated with most other cancer fighting technologies, such as chemotherapies, CAR-T cells, live vector-based vaccines and other immuno-oncology agents.  The safety profile of Versamune®-based products offers great potential for combination with both proven and new cancer therapies.

  • Side effects limited predominantly to transient injection site reactions
  • No dose limiting side effects observed to date
  • No long-term safety concerns

Versamune® is engineered for simplicity and ease of administration.  Versamune® is delivered together with proprietary antigens tailored to individual types of cancer.  The formulation is injected subcutaneously.

PDS Biotech currently holds several patents in major markets, including US, Europe and Japan, providing multiple layers of technology and product protection through at least the mid-2030s.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up